Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2019-05-24
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EF03
|
| gptkbp:CASNumber |
1217486-61-7
|
| gptkbp:chemicalFormula |
C19H22F3N5O2
|
| gptkbp:combines |
gptkb:fulvestrant
|
| gptkbp:contraindication |
hypersensitivity to alpelisib
|
| gptkbp:genericName |
gptkb:alpelisib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Piqray
|
| gptkbp:indication |
gptkb:cancer
HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer |
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:mechanismOfAction |
PI3K inhibitor
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue rash hyperglycemia |
| gptkbp:bfsParent |
gptkb:alpelisib
gptkb:NOVN |
| gptkbp:bfsLayer |
5
|